Johnson & Johnson (JNJ) said Tuesday that investigational nipocalimab has received fast track designation from the US Food and Drug Administration for the treatment of adult patients with moderate to severe Sjogren's disease.
This comes after the investigational therapy was granted breakthrough therapy designation late last year, the company said.
The company said its mid-stage study from last year showed a greater than 70% relative average improvement in systemic disease activity at the 24th week when compared to placebo and IgG reductions of more than 77%.
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。